NPHC · Nutra Pharma Corp
$0.00
At close · Sep 1
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Market Cap
$715,972
Shares
7.16B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.00
Avg vol 30d630K
Short int5K · 0.0% float · 1.0d
Short vol100%
DataJan 2020–Sep 2026
Filing10-Q · Aug 19
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 19, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−50%
below
Price vs 50-day avg
−50%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−75%
trailing
6-month return
0%
trailing
YTD return
0%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -1.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
151%
contracting
Free cash flow
$-1.2M
Balance sheet
$9.7M
net debt
Quant / Vol
risk profile
Volatility
496%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
100.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−50%
Bearish
Price vs 50-day avg
−50%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -1.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -50%
vs 50-day avg -50%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NPHC
this stock
Nutra Pharma Corp
|
$715,972 | +0.0% | +7.9% | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.69B | -1.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.35B | -0.4% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NPHC | +0.0% | -75.0% | +0.0% | +0.0% | +0.0% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | +0.5% | -73.8% | -12.6% | +0.7% | -11.7% |